

Company In-Depth

30 April 2007 | 9 pages

Alok Industries (ALOK.BO)

Buy: Strong 4QFY07, but Pressures Building

 Rating change
 Target price change
 Estimate change

- Operating performance in line** — Revenues and EBITDA grew 41% and 51% respectively on the back of a rapid 119% growth in exports. Earnings growth of 127% was significantly higher due to extraordinary income (forex gain of Rs.296.8m); excluding which growth was still strong at 41%.
- Healthy EBITDA expansion** — Margins expanded 150bps benefiting from higher operating leverage on newly commissioned capacities and better margins in texturizing yarn and garment businesses. We see some pressure going forward, on exports (35% of FY07 revenues) given the sharp rupee appreciation.
- More expansions planned** — With Phase I and II expansions operational, Phase III on backward integration, to go on-stream by Mar'08 – management plans a Phase IV of Rs.11.8bn for adding capacities in spinning, processing, knits and garments by Mar'09. This will be funded through TUF debt (Rs.9.5bn) and internal accruals – this is concerning and could further depress ROCE's.
- Reducing earnings, to factor external pressures** — Building in pressures from the sharp appreciation in rupee on exports (particularly bed linen) and rising interest costs given the high leverage, we reduce our earnings estimates by 12% for FY08-09; despite this, growth still looks strong at 24% CAGR for FY07E-10E.
- Maintain Buy/Medium Risk (1M), lowering target to Rs.76** — Earnings growth momentum strong, higher operating leverage benefits expected, valuations look attractive at 6.3x FY08E; Maintain Buy (1M) with lower target price of Rs.76 based on 8x FY08E P/E, on par with sector as we roll forward to Mar'08.

Buy/Medium Risk	1M
Price (30 Apr 07)	Rs61.85
Target price	Rs76.00
	<i>from Rs100.00</i>
Expected share price return	22.9%
Expected dividend yield	2.4%
Expected total return	25.3%
Market Cap	Rs10,538M
	US\$258M

Price Performance (RIC: ALOK.BO, BB: ALOK IN)



See Appendix A-1 for Analyst Certification and important disclosures.

Figure 1. Statistical Abstract

Year To 31-Mar	FD EPS (Rs.)	EPS Gr. (%)	P/E (x)	ROE (%)
2006	5.1	-12%	11.8	14%
2007	7.3	73%	8.2	19%
2008E	9.5	29%	6.3	18%
2009E	11.8	25%	5.1	19%
2010E	13.9	18%	4.3	20%

Source: Company, CIR estimates

Figure 2. 4Q Earnings Summary (Rs.Mn, %)

	4QFY06	4QFY07	YoY
Net Sales	4,077.4	5,740.8	41%
EBITDA	875.9	1,320.6	51%
EBITDA Margin	21.5%	23.0%	150bps
Interest	172.6	268.5	56%
Other Income	15.0	353.4	nm
Depreciation	215.7	354.2	64%
PBT	502.6	1,051.3	109%
PAT	346.9	786.8	127%

Source: Company Reports

Ashish Jagnani¹

 +91-22-6631-9861
 ashish.jagnani@citigroup.com

Karishma Solanki¹

karishma.solanki@citigroup.com

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

¹Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
Valuation Ratios					
P/E adjusted (x)	12.1	7.0	6.5	5.2	4.4
EV/EBITDA adjusted (x)	7.9	7.6	6.6	5.7	5.2
P/BV (x)	1.5	1.3	1.1	0.9	0.8
Dividend yield (%)	2.4	3.2	3.2	4.9	6.5
Per Share Data (Rs)					
EPS adjusted	5.10	8.80	9.47	11.79	13.90
EPS reported	5.10	8.80	9.47	11.79	13.90
BVPS	40.56	49.45	56.92	65.71	75.28
DPS	1.50	2.00	2.00	3.00	4.00
Profit & Loss (RsM)					
Net sales	14,207	18,290	23,986	28,089	33,202
Operating expenses	-12,054	-15,327	-20,139	-23,383	-27,617
EBIT	2,154	2,962	3,848	4,707	5,586
Net interest expense	-668	-893	-1,250	-1,400	-1,650
Non-operating/exceptionals	54	69	95	95	96
Pre-tax profit	1,540	2,138	2,693	3,402	4,032
Tax	-448	-682	-808	-1,055	-1,250
Extraord./Min.Int./Pref.div.	-76	297	0	0	0
Reported net income	1,016	1,753	1,885	2,347	2,782
Adjusted earnings	1,016	1,753	1,885	2,347	2,782
Adjusted EBITDA	2,958	4,168	5,494	6,466	7,662
Growth Rates (%)					
Sales	15.6	28.7	31.1	17.1	18.2
EBIT adjusted	19.1	37.6	29.9	22.3	18.7
EBITDA adjusted	24.1	40.9	31.8	17.7	18.5
EPS adjusted	-12.0	72.5	7.5	24.5	17.9
Cash Flow (RsM)					
Operating cash flow	2,090	-993	5,313	2,545	2,637
Depreciation/amortization	805	1,205	1,646	1,759	2,076
Net working capital	193	-3,951	1,782	-1,561	-2,221
Investing cash flow	-11,062	-8,364	-4,512	-2,634	-8,600
Capital expenditure	-10,743	-7,956	-5,250	-2,000	-8,500
Acquisitions/disposals	0	0	0	0	0
Financing cash flow	9,043	9,091	5,347	3,603	-1,799
Borrowings	8,256	9,661	5,744	4,200	-1,000
Dividends paid	-299	-398	-398	-597	-800
Change in cash	71	-265	6,148	3,514	-7,762
Balance Sheet (RsM)					
Total assets	33,178	44,305	53,663	60,820	63,107
Cash & cash equivalent	5,370	5,981	11,500	14,978	7,217
Accounts receivable	3,545	5,305	5,670	6,341	7,819
Net fixed assets	18,742	25,493	29,097	29,338	35,762
Total liabilities	24,423	34,459	42,330	47,737	48,040
Accounts payable	1,541	1,750	3,514	4,541	5,619
Total Debt	21,445	31,106	36,850	41,050	40,050
Shareholders' funds	8,755	9,846	11,333	13,083	15,066
Profitability/Solvency Ratios (%)					
EBITDA margin adjusted	20.8	22.8	22.9	23.0	23.1
ROE adjusted	14.5	19.6	17.8	19.2	19.8
ROIC adjusted	8.2	7.3	8.1	9.2	9.6
Net debt to equity	183.6	255.2	223.7	199.3	217.9
Total debt to capital	71.0	76.0	76.5	75.8	72.7

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Key Points

Strong Operating performance in 4QFY07

Alok reported strong 4QFY07 in-line with our expectations. Sales grew 41% with EBITDA growth being stronger at 51%. Exports grew rapidly at 119% driven by strong growth across all business segments – particularly texturized yarn and apparel fabric, bed-linen exports picked up but were lower than expected.

EBITDA margins expanded 150bps YoY benefiting from higher operating leverage, improved product mix and some backward integration benefit in weaving. Higher overheads and staff cost due to the ongoing expansions capped the margin expansion. Despite higher depreciation and interest (continued expansion), earnings grew a robust 127% - due to one-time forex gain on repayment of forex debt; excluding which growth was still strong at 41%.

Figure 3. Earnings Summary (Rupees In Millions, Percent)

	4QFY06	4QFY07	YoY	FY06	FY07	YoY
Net Sales	4,077.4	5,740.8	41%	14,207.1	18,289.7	29%
EBITDA	875.9	1,320.6	51%	2,958.3	4,167.7	41%
EBITDA Margin	21.5%	23.0%	150bps	20.1%	22.2%	210bps
Interest	172.6	268.5	56%	667.8	893.4	34%
Other Income	15.0	56.6	277%	54.1	69.3	28%
Depreciation	215.7	354.2	64%	804.8	1,205.4	50%
PBT	502.6	754.5	50%	1,539.8	2,138.2	39%
PAT	346.9	490.0	41%	1,091.9	1,456.0	33%
Extraordinary	-	296.8		-	296.8	
PAT after Extraordinary	346.9	786.8	127%	1,091.9	1,752.8	61%

Source: Company Reports

More expansions planned

The company has further embarked on a Phase IV of expansion entailing Rs.11.8bn – primarily for adding capacities in spinning, processing of apparel fabric, knit weaving and processing, garments and made-ups. As per management this will be funded through a mix of debt (Rs.9.5bn) and internal accruals and would be operational by Mar'09. While this will build on overall scale, it is aggressive in our view. Given that company is still to realize the full benefits of its newly commissioned capacities and we believe this will continue to hinder improvement in ROCE's.

Figure 4. Existing and Planned capacity

Segment	Existing	Phase III	Phase IV	Total
Texturizing Yarn (TPA)	85,000			85,000
POY Plant	54,000			54,000
Weaving				
Fabric (mn mtrs)				
Apparel Fabric	57.5	25.0		82.5
Home Textiles	45.2	24.8		70.0
Knit (TPA)	16,800		50,400	67,200
Yarn (Ring Frame) TPA (MT)	5,250	15,000	9,750	30,000
Processing				
Apparel Fabric (mn mtrs)	82.5		22.5	105.0
H.Textiles Fabric (mn mtrs.)	60.0	22.5		82.5
Knit Fabric (TPA)	16,800		50,400	67,200
Yarn Dyeing (TPA)	3,000			3,000
Bed Linen (mn sets)	6.0	4.0	3.8	13.8
Garments (mn pcs)	8.0	7.0	7.0	22.0
Terry Towels (TPA)	6,700			6,700
Open Ended Yarn (TPA)	2,000			2,000

Source: Company Reports and Citigroup Investment Research

Lowering our earnings estimates

We are lowering our earnings estimates by 12% over FY08 and FY09, to account for building pressures from the sharp appreciation in rupee on exports (particularly bed linen – 20% of revenues) and rising interest costs given the high leverage (debt/equity of 3.2x in FY07E). Lowering of estimates was triggered by 9% lower than expected earnings (excluding extra-ordinaries) in FY07 due to 1) lower revenues in bed-linen following appreciating rupee and 2) lower other income. With the company's forward cover on exports until July'07; we expect pressure on realizations for some repeat orders in bed-linen. Factoring this, we have reduced our revenue and EBITDA estimates by 2% and 4% respectively for FY08E and FY09E. While large part (55%) of the company's debt is under low cost Technology Upgradation Fund scheme, given the high leverage of 3.2x FY07E, we expect interest cost to increase going forward. Factoring this, we have reduced our earnings estimates by 12% for FY08 and FY09. However, building for this and our expectation of higher operating leverage as more of expansion gets operational– we forecast an earnings growth of 18.5% for FY2010E. Factoring which, we still expect strong earnings CAGR of 24% over FY07-2010E.

Figure 5. Earnings revision summary

Year to	FY07			FY08E			FY09E		
	Actual	Estimates	% Chg	New	Old	% Chg	New	Old	% Chg
31-Mar									
Revenue	18,290	19,083	-4.2	23,986	24,553	-2.3	28,089	28,804	-2.5
EBITDA	4,168	4,389	-5.0	5,494	5,762	-4.6	6,466	6,848	-5.6
Net Profit	1,456	1,603	-9.2	1,885	2,147	-12.2	2,347	2,666	-12.0
FD EPS	7.3	8.05	-9.2	9.5	10.8	-12.2	11.8	13.4	-12.0

Source: Citigroup Investment Research estimates

Alok Industries

Company description

Alok has the largest textile processing capacity (142.5m meters) in India. Its manufacturing facilities, superior quality, wide product range in apparel fabrics (43% of FY07 revenues) and home textiles (20% of FY07 revenues) have made it a preferred vendor for global retailers such as Wal-Mart, JC Penny, GAP and garment exporters in India. It spans the textile value chain, with completely integrated facilities for yarn texturizing (27% of revenues), weaving, knitting, processing, made-ups and garments. Exports make up 35% of its revenues; but with the phasing out of quotas, the company's ramp-up in home textiles and its thrust on exports, we expect the share of exports to increase to 34% in FY08. It is controlled and managed by the Jiwrajka family, with the major shareholders owning a 29% stake.

Investment thesis

We maintain a Buy/Medium Risk (1M) rating on Alok with a target price of Rs.76 based on 8x FY08E P/E, on par with the sector. Our thesis is premised on the strong growth opportunity in home textiles and Alok's major expansions in weaving-processing capacities of bed linen and apparel fabric now operational. We see this providing the company with significant operating leveraging and earnings CAGR of 27% over FY07-09E.

Key growth drivers are 1) More expansions going on-stream over next two years; 2) thrust on diversifying to a richer product mix; 3) growing order book for exports; and 4) benefits of backward integration. While external pressures are mounting with appreciating rupee and rising interest costs, building for which we still forecast healthy growth potential. Its presence across a significant part of the textile value chain and close ties with global retailers should help exploit the outsourcing opportunities in the sector and improve margins. However we expect the company's aggressive expansion and newly announced Phase IV expansion will hinder improvement of ROCE's.

Valuation

We are lowering our target price from Rs.100 to Rs.76. Our revised target price is based on 8x FY08E P/E, still on par with Citigroup's textile sector (consisting of eight other stocks – Arvind Mills, Raymond, Gokaldas Exports, Welspun India, Mahavir Spinning, JCT, Abhishek Industries and S Kumar Nationwide), which we now value at 8x FY08E P/E (12.5x FY07E P/E earlier), as we have rolled over our base assumption from Sep'07 to Mar'08. The stock is trading at the lower end of its historical P/E band of 6-12x over the past two years – we see this trend breaking out going forward and expect valuations to catch up with our textile universe. Better earnings growth on the back of recently commissioned capacities, richer product mix and management's assurance of no further equity dilutions – are the key reasons we expect this. Because P/E captures the earnings growth potential of a company, we consider it as our primary valuation method.

Risks

We rate Alok Industries Medium Risk in view of most parts of phase II expansion now being operational and risks of further delay in commissioning of new capacities having reduced. However, risk of any equity dilutions and the prospect of the company reporting the lowest ROCE of 6% in the sector still remain. The Medium risk is in line with our quantitative risk rating system, which tracks 260-day volatility of the shares.

The main company specific risks that could impede that stock from reaching our target price include:

- Delay in commissioning of new capacity by a quarter would push back the growth we are projecting for FY07-08;
- Significant increase in interest cost, would adversely impact earnings growth assumption – given its high leverage (debt/equity at 3.2x FY07E);
- Sharp increases in cotton prices by more than 10% from Rs.50/kg would impact profitability by 7-8%, on our estimates;
- appreciation of the rupee by more than 5% from the base level of Rs41 will reduce price realizations of exports, which contributed 35% of FY07 revenues but which are expected to increase sharply as new capacity goes on stream;
- Any over-priced acquisition of spinning/garmenting facilities in its bid to backward integrate its home textiles business.

Appendix A-1

Analyst Certification

I, Ashish Jagnani, research analyst and the author of this report, hereby certify that all of the views expressed in this research report accurately reflect my personal views about any and all of the subject issuer(s) or securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

Alok Industries (ALOK.BO)

Ratings and Target Price History - Fundamental Research

Analyst: Ashish Jagnani (covered since October 21 2005)



Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Alok Industries. This position reflects information available as of the prior business day.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Alok Industries in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Alok Industries.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Alok Industries.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution

Data current as of 31 March 2007

	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3215)	45%	40%	15%
% of companies in each rating category that are investment banking clients	45%	42%	32%
India -- Asia Pacific (130)	58%	14%	28%
% of companies in each rating category that are investment banking clients	42%	50%	42%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected

performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citigroup Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citigroup Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citigroup Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at <http://www.sd.ny.ssmb.com/> using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperform the relevant sector of the Citigroup indexes.

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 30 April 2007 10:23 AM on the issuer's primary market.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Alok Industries.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Alok Industries.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product

was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartościowych i Giełd. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gashka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
